SCHEMBL4174196

SCHEMBL4174196

FC(F)(F)c1ccc(-c2nnc(N(Cc3ccccc3)C3=COCO3)[nH]2)c(NCc2cccnc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SORT1 Q99523 1/20 0.37
LMNA P02545 1/20 0.37
KDR P35968 2/20 0.35
MET P08581 1/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2C19 P33261 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
NAMPT P43490 2/20 0.34
VNN1 O95497 3/20 0.34
DDR1 Q08345 1/20 0.34
DDR2 Q16832 1/20 0.34
CYP2C9 P11712 1/20 0.34
PLK1 P53350 1/20 0.34
CYP11B1 P15538 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178551 0.92 KDR (0.36) SORT1KDRVNN1CYP11B1CYP11B2
SCHEMBL4181696 0.86 MEN1 (0.37) KDM4EALDH1A1
SCHEMBL4181723 0.81 CYP1A2 (0.42) KDM4EALDH1A1LMNAKDRCYP3A4
SCHEMBL4173263 0.79 KDR (0.40) KDM4EKDRKDM4C
SCHEMBL4170614 0.74 KDR (0.43) KDM4EALDH1A1LMNAKDRCYP3A4
SCHEMBL4174895 0.73 KDR (0.48) KDRCLK4
SCHEMBL4174192 0.72 ALDH1A1 (0.53) KDM4EALDH1A1KDRCYP3A4CYP2C19
SCHEMBL4180846 0.72 TUBB4A (0.43) KDM4EALDH1A1KDRCLK4
SCHEMBL4181413 0.72 QPCT (0.33) KDR
SCHEMBL4181336 0.69 TUBB4A (0.40) KDM4EALDH1A1LMNAKDRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL KDM4E 2144/4885ALDH1A1 535/4885SORT1 4558/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL KDM4E 2144/4885ALDH1A1 535/4885SORT1 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.